iCell Hepatocytes 2.0, 01279

The medical community needs a reproducible, well-characterized, and readily available source of human hepatocytes to advance signific tillitmatantly the launch of new metabolic and infectious disease therapies, reduce the incidence of drug-induced liver injury, and accelerate the development of novel approaches to liver regeneration and transplantation. To meet this need, CDI has leveraged iPS cell technology to develop iCell® Hepatocytes. These hepatocytes overcome the functionality, reproducibility, and availability limitations of existing primary cell and tumor-derived cell models by providing the following:

• Relevant hepatic functionality and phenotypic stability
• Expression of clinical targets that are relevant for liver and metabolic disease
• Compatibility with a wide range of 3D and microphysiological systems
• Quality-controlled manufacturing and batch reproducibility
• Ready supply in a cryopreserved format

Proven Applications

iCell Hepatocytes 2.0 are being rapidly adopted for use in a wide range of applications:

• Diabetes research and drug discovery
  Functional INS and glucose regulation pathways and a flexible product format enable high-throughput screening for novel drug candidates.
• Infectious disease studies
  Native human biology and long-term phenotypic stability support hepatitis viral replication including growth of clinically relevant genotypes (Ng et al., 2015; Mann et al., 2013; Schlomai et al., 2013; CDI Application Note).
• Hepatotoxicity assessment
  Known genetic background and proven ability to detect metabolism-dependent and immune-mediated hepatotoxicity provide confidence in safety testing without the need for time-consuming and costly lot testing (Sirenko et al., 2013; Mann, 2014; Lu et al., 2015).
• Liver tissue engineering
  Compatibility with bioengineered scaffold engraftment, organ recellularization, and 3D printing enable new clinical and regenerative medicine strategies (Berger et al., 2015; Ware et al., 2015).
• 3D spheroid culture
  iCell Hepatocytes form stable, highly uniform spheroids in low attachment plates under a protocol developed at CDI enabling more in vivo-like three dimensional culture and applications.